The SEC avers that Panuwat learned of the pending acquisition of Medivation by a large pharmaceutical company, Inc. through his position at Medivation prior to the public announcement of the deal. The complaint alleges that Panuwat then purchased out-of-the-money short-term call options for the common stock of Incyte Corporation, an unrelated company that was positioned similarly in the market to Medivation.